As of March 31, 2013, Cadence held cash, cash equivalents and short-term investments of $64.2 million, an increase of $2.1 million from the $62.1 million at December 31, 2012. Net accounts receivable at March 31, 2013, was $8.9 million.
GuidanceAs of May 2, 2013, Cadence is increasing its guidance to reflect the impact of the deferred revenue recognized in the first quarter of 2013. It now expects that net product revenue from sales of OFIRMEV for the twelve months ending December 31, 2013, will range from approximately $97.0 million to $103.0 million.
Conference Call and Webcast on May 2, 2013 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) Cadence management will host a conference call on May 2, 2013, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.
About OFIRMEV® (Acetaminophen) InjectionOFIRMEV (acetaminophen) injection (1000 mg / 1
|SOURCE Cadence Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved